Drug intelligence / Profile preview

BI 479 V1

Development stage: Preclinical
Lead developer: Boehringer Ingelheim
Modality: Small Molecules
Administration: Topical

Overview

BI 479 V1 is an investigational product studied for topical application, specifically in clinical trials assessing its efficacy and tolerance in conditions involving dry skin. The exact molecular structure, mechanism of action, and targeted indication are not established in public datasets or literature. It is tested as a topical intervention, compared to placebo, to measure skin hydration outside flare-up areas in subjects with initial dry skin[3]. No information on its molecular pharmacology, target, or therapeutic class is available.

Beyond the preview

Go deeper on BI 479 V1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BI 479 V1.

Explore the full profile